BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Go back to BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 64.06 +0.12 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.94 | 52 Week High | $108.96 | |||
| Open | $64.35 | 52 Week Low | $62.12 | |||
| Day High | $64.96 | P/E | N/A | |||
| Day Low | $63.58 | EPS | $-1.27 | |||
| Volume | 1,877,005 | |||||
